Mineralocorticoid Receptor and Obesity Induced Cardiovascular Complications

Completed · Not applicable · Has a placebo group

Conditions studied: Obesity, Insulin Resistance

In brief

The purpose of this study is to find out if spironolactone, a drug that blocks the action of aldosterone, can make the blood vessels work better in people with obesity. The investigators also want to find out whether spironolactone causes changes in levels of insulin and markers of inflammation.

Key facts

Study ID

NCT01406015

Run by

Brigham and Women's Hospital

People needed

38

Starts

2009-02-01

Expected to finish

2013-12-01

Last updated by the study team

2017-04-28

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18-70 years
• Good health as evidenced by history and physical exam
• Body Mass Index (BMI): >30 kg/m2 and <45 kg/m2

You may not qualify if…

• Medical illnesses other than treated hypothyroidism
• Blood Pressure (BP) >135/85 or systolic BP <90 mm Hg
• Hepatic disease (transaminase > 3 times normal)
• Renal impairment (Creatinine clearance <60 ml/min)
• Baseline serum Potassium (K) >5.0 mmol/L
• History of drug or alcohol abuse
• Allergies to spironolactone
• Participation in any other concurrent clinical trial
• Women using oral contraceptives within the last 3 months

Where it is running

• Brigham and Women's Hospital — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.